The main drivers in NAFLD are inflammation and accumulation of lipids [40], and L-carnitine has been shown to have anti-inflammatory effects by upregulating the peroxisome proliferator activator receptor-γ (PPAR-γ) in the liver [41]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.